Key facts
- Genvax Technologies’s last known valuation is $25.0M (Aug 2022).
- It has raised $8.4M across 2 recorded rounds; the latest was Seed Round ($3.4M) in Jun 2024.
- Notable investors include United States Department of Agriculture, Next Level Ventures, Ag Ventures Alliance, 1945 Capital, Ag Startup Engine — 11 tracked in total.
- Genvax Technologies has filed 2 Form Ds with the SEC since 2022, most recently Jun 2024 ($3.4M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Genvax Technologies
Funding rounds
2 roundsAbout Genvax Technologies
Developer of animal vaccines designed to accelerate treatments for the animal health industry. The company's saRNA platform allows for the rapid development of herd or flock-specific vaccines matched to the variant strain circulating in an animal-production operation by inserting a specific transgene or gene of interest matched to the variant strain into the platform, providing clients from the animal health industry with novel vaccines for the prevention and treatment of animal diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Ames, IA, United States
- Founded
- 2021
- Employees
- 9
- Website
- genvax.com/
- Ownership
- Privately Held (backing)
Genvax Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genvax Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genvax Technologies in its N-PORT filings yet. We sweep new filings monthly.